Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.47 |
| ▸ | F10 | P00742 | 5/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848001 | 1.00 | F2 (0.47) | F2F10PRSS1PNPALDH1A1 | |
| SCHEMBL563435 | 0.86 | F10 (0.48) | F2F10PRSS1ALDH1A1HPGD | |
| SCHEMBL14691022 | 0.86 | FNTA (0.51) | F2F10PRSS1PNPALDH1A1 | |
| SCHEMBL14691320 | 0.86 | F2 (0.50) | F2F10PRSS1PNPALDH1A1 | |
| SCHEMBL21656114 | 0.85 | GABBR2 (0.41) | ALDH1A1HPGDGABBR2GABBR1LMNA | |
| SCHEMBL23750165 | 0.84 | GABBR2 (0.47) | ALDH1A1HPGDGABBR2GABBR1LMNA | |
| SCHEMBL23750201 | 0.84 | GABBR2 (0.47) | ALDH1A1HPGDGABBR2GABBR1LMNA | |
| SCHEMBL24036585 | 0.82 | PNP (0.47) | PNPALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL4938396 | 0.82 | PNP (0.47) | PNPALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL21610492 | 0.82 | GABBR2 (0.67) | GABBR2GABBR1LMNACYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-112789287-B | Compounds of formula (I) | 云顶新耀医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4316504-A2 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3810633-B1 | COMPOUNDS | SPERO THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11459357-B2 | Polymyxin compounds | SPERO THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| CN-112789287-A | Compound (I) | 斯佩罗治疗公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3810633-A1 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | F2 543/4885F10 1162/4885PRSS1 2340/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | F2 870/4885F10 1945/4885PRSS1 2389/4885 |
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | F2 315/4885F10 289/4885PRSS1 497/4885 |
| US-11459357-B2 | Polymyxin compounds | MRPL37, MRPS18A, PNISR | F2 451/4885F10 315/4885PRSS1 365/4885 |
| US-20210246169-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPS35 | F2 288/4885F10 229/4885PRSS1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.